Detection Of A Novel Antituberculosis Drug Bedaquiline-resistant Gene In Clinical Specimens Of Tuberculosis

Objective:To understand the tuberculosis patient resistance to Bedaquiline before the use of it and to provide lab data for the treatment of Bedaquiline in Drug-resistant tuberculosis.Methods:Mycobacterium tuberculosis culture and Antituberculosis drug sensitivity test were performed on Mycobacterium tuberculosis clinical specimens to screen for sensitive and drug-resistant Mycobacterium tuberculosis.The CTAB method was used to extract the DNA of the strain.The genomic DNA from the resistance genes of Bedaquiline,Rv0678,atp E and pep Q,was amplified respectively by polymerase chain reaction(PCR)to obtain the genotypes of Mycobacterium tuberculosis.Sequencing results were aligned with the M.tuberculosis H37 Rv gene sequence at the National Center for Biotechnology Information,Finally analyzed the results.Results:three drug resistance genes(pep Q,atp E and Rv0678)were detected in 70 sensitive and 57 drug-resistant Mycobacterium tuberculosis clinical isolates in this study.No mutation of pep Q,atp E and Rv0678 was detected in sensitive Mycobacterium tuberculosis(0/70).Two mutations of Rv0678(TCC155TTC,GGG193TGG)were detected in drug-resistant Mycobacterium tuberculosis,The detection rate was 3.5%(2/57).Pep Q and atp E mutations were not detected.The overall detection rate of Rv0678 mutation in Mycobacterium tuberculosis was 1.6%(2/127).Conclusion:Approximately 3.5% of patients with Drug-resistant tuberculosis(DR-T B)were at risk of resistance to Bedaquiline before using the new anti-tuberculosis drug to treat drug-resistant TB,suggesting that Mycobacterium tuberculosis phenotype or genotype should be tested before clinical treatment to improve the success rate of treatment.